Business Context and Reporting Period
This Form 6-K filing by Galmed Pharmaceuticals Ltd. is dated August 14, 2026, covering the month of August 2026. The filing announces a corporate action regarding the Company's capital structure rather than reporting operational financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share capital adjustments.
Material Changes
- Reverse Share Split: The Company will effect a 1-for-8 reverse share split.
- Share Count Adjustment: Issued and outstanding ordinary shares will decrease from 8,332,518 to approximately 1,041,565.
- Par Value Adjustment: The par value per share will increase from NIS 1.80 to NIS 14.40.
- Authorized Capital: Post-split authorized share capital will consist of 112,500,000 ordinary shares.
- Trading Resumption: Trading on the Nasdaq Capital Market under the new structure will commence on Wednesday, August 19, 2026.
- Fractional Shares: No fractional shares will be issued; holdings will be rounded to the nearest whole share, with only fractions exceeding one-half of a share receiving a consolidated share.
- Derivatives: Proportionate adjustments will be made to the exercise price and share count for all outstanding warrants and options.
- CUSIP Update: The new CUSIP number for ordinary shares is M47238205.
Guidance, Outlook, and Risks
The filing does not contain management commentary on business outlook, financial guidance, or specific risk factors beyond the mechanics of the share split. The document notes that the number of outstanding shares is subject to further adjustments based on the treatment of fractional shares.
Investor Verification Checklist
- Verify the effective date of the reverse split (August 19, 2026) and the new CUSIP number (M47238205) with brokerage accounts.
- Confirm the treatment of fractional shares held in the portfolio to determine if rounding will result in a loss of value.
- Review the adjusted exercise prices and share quantities for any held options or warrants.
- Monitor the Company's Form 20-F for the next available financial performance data, as this filing contains no operational metrics.